These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 15154652)

  • 1. Cellular immunomodulation and safety of standardized aqueous mistletoe extract PS76A2 in tumor patients treated for 48 weeks.
    Dohmen W; Breier M; Mengs U
    Anticancer Res; 2004; 24(2C):1231-7. PubMed ID: 15154652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial.
    Semiglazov VF; Stepula VV; Dudov A; Schnitker J; Mengs U
    Anticancer Res; 2006; 26(2B):1519-29. PubMed ID: 16619567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of antibodies to viscotoxins A1, A2, A3, and B in tumour patients during therapy with an aqueous mistletoe extract.
    Klein R; Classen K; Fischer S; Errenst M; Scheffler A; Stein GM; Scheer R; von Laue HB
    Eur J Med Res; 2002 Aug; 7(8):359-67. PubMed ID: 12204844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Value of mistletoe lectin standardized mistletoe extract for evaluating antitumor properties].
    Mengs U; Witthohn K; Schwarz T; Lentzen H
    Wien Med Wochenschr; 1999; 149(8-10):262-4. PubMed ID: 10483695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial.
    Semiglasov VF; Stepula VV; Dudov A; Lehmacher W; Mengs U
    Anticancer Res; 2004; 24(2C):1293-302. PubMed ID: 15154663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a mistletoe preparation with defined lectin content on chronic hepatitis C: an individually controlled cohort study.
    Huber R; Lüdtke R; Klassen M; Müller-Buscher G; Wolff-Vorbeck G; Scheer R
    Eur J Med Res; 2001 Sep; 6(9):399-405. PubMed ID: 11669085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a standardized mistletoe preparation on metastatic B16 melanoma colonization in murine lungs.
    Weber K; Mengs U; Schwarz T; Hajto T; Hostanska K; Allen TR; Weyhenmeyer R; Lentzen H
    Arzneimittelforschung; 1998 May; 48(5):497-502. PubMed ID: 9638318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of immune cell activities and beta-endorphin release in breast carcinoma patients treated with galactose-specific lectin standardized mistletoe extract.
    Heiny BM; Albrecht V; Beuth J
    Anticancer Res; 1998; 18(1B):583-6. PubMed ID: 9568181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of postoperative complementary treatment with lectin-standardized mistletoe extract on breast cancer patients. A controlled epidemiological multicentric retrolective cohort study.
    Schumacher K; Schneider B; Reich G; Stiefel T; Stoll G; Bock PR; Hanisch J; Beuth J
    Anticancer Res; 2003; 23(6D):5081-7. PubMed ID: 14981970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunoactive effects of various mistletoe lectin-1 dosages in mammary carcinoma patients].
    Beuth J; Stoffel B; Ko HL; Buss G; Tunggal L; Pulverer G
    Arzneimittelforschung; 1995 Apr; 45(4):505-7. PubMed ID: 7779151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoprotective activity of the galactoside-specific mistletoe lectin in cortisone-treated BALB/c-mice.
    Beuth J; Ko HL; Tunggal L; Buss G; Jeljaszewicz J; Steuer MK; Pulverer G
    In Vivo; 1994; 8(6):989-92. PubMed ID: 7772751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lectin-related use of mistletoe: an experimental form of treatment with preclinically demonstrated potential risks].
    Gabius S; Gabius HJ
    Dtsch Med Wochenschr; 2002 Mar; 127(9):457-9. PubMed ID: 11870561
    [No Abstract]   [Full Text] [Related]  

  • 13. [Immunoactive action of mistletoe lectin-1 in relation to dose].
    Beuth J; Ko HL; Tunggal L; Buss G; Jeljaszewicz J; Steuer MK; Pulverer G
    Arzneimittelforschung; 1994 Nov; 44(11):1255-8. PubMed ID: 7848341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standardized mistletoe extract augments immune response and down-regulates local and metastatic tumor growth in murine models.
    Braun JM; Ko HL; Schierholz JM; Beuth J
    Anticancer Res; 2002; 22(6C):4187-90. PubMed ID: 12553054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial.
    Friess H; Beger HG; Kunz J; Funk N; Schilling M; Büchler MW
    Anticancer Res; 1996; 16(2):915-20. PubMed ID: 8687151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mistletoe extract standardized for the galactoside-specific lectin (ML-1) induces beta-endorphin release and immunopotentiation in breast cancer patients.
    Heiny BM; Beuth J
    Anticancer Res; 1994; 14(3B):1339-42. PubMed ID: 8067703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo-induction of antibodies to mistletoe lectin-1 and viscotoxin by exposure to aqueous mistletoe extracts: a randomised double-blinded placebo controlled phase I study in healthy individuals.
    Klein R; Classen K; Berg PA; Lüdtke R; Werner M; Huber R
    Eur J Med Res; 2002 Apr; 7(4):155-63. PubMed ID: 12010650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of cellular and humoral immune responses during exposure of healthy individuals to an aqueous mistletoe extract.
    Stein GM; Berg PA
    Eur J Med Res; 1998 Jun; 3(6):307-14. PubMed ID: 9620894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group.
    Schöffski P; Riggert S; Fumoleau P; Campone M; Bolte O; Marreaud S; Lacombe D; Baron B; Herold M; Zwierzina H; Wilhelm-Ogunbiyi K; Lentzen H; Twelves C;
    Ann Oncol; 2004 Dec; 15(12):1816-24. PubMed ID: 15550588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of an antitumoral effect of immunomodulatory galactoside-specific mistletoe lectin on N-methyl-N-nitrosourea-induced urinary bladder carcinogenesis in rats.
    Kunze E; Schulz H; Ahrens H; Gabius HJ
    Exp Toxicol Pathol; 1997 Aug; 49(3-4):167-80. PubMed ID: 9314050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.